Low molecular weight heparin in COVID-19 patients prevents delirium and shortens hospitalization.
Neurol Sci
; 42(4): 1527-1530, 2021 Apr.
Article
em En
| MEDLINE
| ID: mdl-33185785
ABSTRACT
BACKGROUND:
COVID-19 patients present with delirium during their hospitalization.AIMS:
To assess the incidence of delirium in hospitalized COVID-19 patients and analyze the possible association with demographic, clinical, laboratory, and pharmacological factors.METHODS:
COVID-19 patients were assessed for clinical signs of delirium and administered the assessment test for delirium and cognitive impairment (4AT) and the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) scales.RESULTS:
Out of the 56 patients of our cohort, 14 (25.0%) experienced delirium. The use of low molecular weight heparin (LMWH) (enoxaparin 1 mg/kg/daily) was less frequent in patients with delirium (p = 0.004) and was accompanied by lower C reactive protein (CRP) levels (p = 0.006).DISCUSSION:
The use of LMWH was associated with absence of delirium, independently of comorbidities and age.CONCLUSIONS:
The use of LMWH may help preventing the occurrence of delirium in COVID-19 patients, with possible reduction of length of stay in the hospital and sequelae.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Enoxaparina
/
Heparina de Baixo Peso Molecular
/
Delírio
/
COVID-19
/
Anticoagulantes
Tipo de estudo:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Risk_factors_studies
Limite:
Aged
/
Aged80
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Neurol Sci
Assunto da revista:
NEUROLOGIA
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Itália